Disclaimer

Featured Papers now available free for a limited time only CS Featured Papers are available as PDF limited time offer

Original contributed article by authorsKreyenbuhl, Record, Himelhoch, Charlotte, Palmer-Bacon, Dixon, Medoff, Li   Original contributed article by authors Marilyn J. Miller, Donna M. Ambrose   New download article by Nemani, Greene, Ulloa, Vincenzi, Copeland, Al-Khadari, Henderson   New Drug Study by Ehret, Davis, Luttrell, Clark
Clinical News by Peter F. Buckley   A Guide to the Management of Drug-Related Tolerability and Safety Concerns   Featured paper by Michael A. Cummings, George J. Proctor, Stephen M. Stahl   Brain Natriuretic Peptide as a Biomarker of Asymptomatic Clozapine-Related Heart Dysfunction
Refresh your browser [F5] to get the newest content available.

About Us

The vision of the exciting new peer-reviewed quarterly publication Clinical Schizophrenia & Related Psychoses (CS) is to provide psychiatrists and other healthcare professionals with the latest research and advances in the diagnosis and treatment of schizophrenia and related psychoses. CS is a practice-oriented publication focused exclusively on the newest research findings, guidelines, treatment protocols, and clinical trials relevant to patient care.

Distributed free to the 23,642 highest U.S. prescribers of antipsychotic drug therapies, advertising in CS is limited to 6 to 8 ads per issue, providing maximum exposure for our select sponsors.

Editorial Mission

CS presents peer-reviewed original research and analysis that deals exclusively with the treatment of schizophrenia and related psychoses and is directly relevant to patient care through:

Author Submissions:   For Reviewers:
Author Submission to Walsh Medical Media Clinical Schizophrenia Quarterly Journal   Author Submission to Walsh Medical Media Quarterly Journal of Clinical Schizophrenia

For any questions concerning our online manuscript system, contact: Karen Horn

CS is indexed in Medline/PubMed/IndexMedicus, Scopus, and EMBASE.

For additional information please contact us at: More Information